Clinical trial · Observational
An Observational Study of Herceptin (Trastuzumab) in Patients With HER2-positive Advanced Gastric Cancer
Clinical Practice Surveillance of the Use of Herceptin in Patients With HER2-positive Advanced Adenocarcinoma of the Stomach or Gastro-esophageal Junction (GEJ) (HERMES)
NCT01220934CI-TRIAL-00033370completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This observational, multicenter study will assess the efficacy and safety of Herceptin (trastuzumab) in routine clinical practice in patients with HER2-positive advanced adenocarcinoma of the stomach or gastro-esophageal junction. Data from patients will be collected for approximately 12 months.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- Cohort
Primary outcomes (3)
- measure
- Response rate according to Response Evaluation Criteria in Solid Tumors (RECIST)
- timeFrame
- 12 months
- measure
- Progression-free survival according to Response Evaluation Criteria in Solid Tumors (RECIST)
- timeFrame
- 12 months
- measure
- Overall survival according to Response Evaluation Criteria in Solid Tumors (RECIST)
- timeFrame
- 12 months
Secondary outcomes (7)
- measure
- Documentation of the testing process for HER2-positive tumors
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adult patients, \>/=18 years of age * Histologically confirmed advanced adenocarcinoma of the stomach or gastro-esophageal junction (GEJ) with locally advanced and/or metastatic disease * HER2-positive tumor * Patients who are eligible for treatment with Herceptin according to the judgment of the physician Exclusion Criteria: * Unwilling or unable to sign informed consent form * Any contraindications, interactions and incompatibilities to Herceptin
References
Publications (0)
Data not yet available
No reference posted for this study.